期刊文献+

62例深静脉血栓患者华法林用药分析 被引量:3

Application of Warfrain on Deep Venous Thrombosis:A Review on 62 Patients
下载PDF
导出
摘要 目的:了解我院深静脉血栓患者华法林用药情况及存在的问题并提出建议,促进临床合理用药。方法:对2013年10月~2014年3月我院服用华法林治疗深静脉血栓的住院患者病历进行回顾性调查分析,调查内容包括在院期间华法林联合用药、用药期间国际标准化比值(INR)监测、华法林剂量调整等情况,并参照国内外指南进行综合评价和分析。结果:共收集62例患者病历,我院尚存在患者服用华法林期间联用药物种类多、INR监测不规范、华法林剂量调整不及时、住院期及出院前INR达标率低等问题。结论:目前我院华法林用药尚存在不足,需参照指南制定华法林用药规范,指导临床合理使用华法林进行抗凝治疗。 Objective:To investigate application of warfrain on deep venous thrombosis among our hospital, discover the existed problem and seek for solution, in order to promote the rational drug use. Methods:The inpatient cases between October 2013 to March 2014 diagnosed of deep venous thrombosis were collected, who were given warfrain for an- tithrombotie therapy. The drug combination, INR-monitoring and close adjustment of warfrain, base on the guideline at home and abroad were appraised. Results: A total of 62 cases were enrolled and appraised. It showed that patients in our hospital who were consuming warfrain turned to receive various kinds of medicine altogether. With irregular INR monitoring and delayed dose adjustment, most of the patients could not achieve the therapeutic range measured by INR. Conclusion: At the present, the application of warfrain in our hospital was undesirable. Medicine practice of warfrain needed to be for- mulated according to the available guideline. Under the instruction of the practive, we could anticipate that warfrain would be used more rationally.
出处 《药物流行病学杂志》 CAS 2015年第9期547-550,共4页 Chinese Journal of Pharmacoepidemiology
关键词 深静脉血栓 华法林 国际标准化比值 合理用药 Deep venous thrombosis Warfrain INR Rational drug use
  • 相关文献

参考文献9

  • 1马丁代尔药物大典[S].第37版.2013.1368.
  • 2Kearon C, Akl, EA, Comerota, A J, et al. Antithrombotic therapy for VTE disease [ J ]. Chest, 2012, 141 (2Suppl) : e419S-e494S.
  • 3Holbrook A, Schulman S, Witt DM, et al. Evidence-based management of anticoagulant therapy [ J ]. Chest, 2012,141 (2Suppl) :e152S-e184S.
  • 4Ageno W, Gallus AS, Wittkowsky A,et al. Oral anticoagu- lant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines [ J ]. Chest, 2012, 141(2Suppl) :e44S-e88S.
  • 5National comprehensive cancer network. Cancer-associate venous thromboembolic disease [ DB/OL ]. http : //guide.medlive, cn/guideline/6585 ,2014-05-30/2014-07-08.
  • 6Meissner MH, Gloviczki P, Comerota AJ, et al. Early thrombus removal strategies for acute deep venous thrombo- sis: clinical practice guidelines of the Society for Vascular Surgery and the American Venous Forum [ J ]. J Vasc Surg, 2012,55 (5) : 1449-1462.
  • 7深静脉血栓形成的诊断和治疗指南(第2版)[J].中华外科杂志,2012,50(7):611-614. 被引量:502
  • 8华法林抗凝治疗的中国专家共识[J].中华内科杂志,2013,52(1):76-82. 被引量:605
  • 9胡大一.华法林临床应用专家共识[DB/OL].http:∥guide.medlive.cn/guideline~4883,2013-10-13/2014-07-08.

二级参考文献16

  • 1胡大一,张鹤萍,孙艺红,姜立清.华法林与阿司匹林预防非瓣膜性心房颤动患者血栓栓塞的随机对照研究[J].中华心血管病杂志,2006,34(4):295-298. 被引量:162
  • 2Hirsh J, Fuster V, Ansell J, et al. American Heart Association/ American College of Cardiology Foundation guide to warfarin therapy. J Am Coil Cardiol, 2003,41:1633-1652.
  • 3Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med, 2007, 146:S57-867.
  • 4Hu D, Sun Y. Epidemiology, risk factors for stroke, and management of atrial fibrillation in China. J Am Coil Cardiol, 2008, 52: 865-868.
  • 5Rieder MJ, Reiner AP, Gage BF, et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med, 2005,352:2285-2293.
  • 6Aithal GP, Day CP, Kesteven PJ, et al. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet, 1999, 353:717-719.
  • 7Ageno W, Gallus AS, Wittkowsky A, et al. Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest, 2012, 141 (2 Suppl) :eddS- 88S.
  • 8Holbrook A, Schulman S, Witt DM, et al. Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest, 2012, 141 (2 Suppl) :e152S-184S.
  • 9Manolopoulos VG, Ragia G, Tavridou A. Pharmacogenetics of coumarinic oral anticoagulants. Pharmacogenomics, 2010, 11 : 493 -496.
  • 10Schulman S, Parpia S, Stewart C, et al. Warfarin dose assessment every 4 weeks versus every 12 weeks in patients with stable international normalized ratios: a randomized trial. Ann Intern Med, 2011,155:653-659.

共引文献1103

同被引文献27

引证文献3

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部